Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study.

cytoreduction ovarian cancer population analysis radical surgical complexity survival ultra-radical

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
07 Sep 2022
Historique:
received: 12 08 2022
revised: 02 09 2022
accepted: 03 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

We investigated URS and impact on survival in whole patient cohorts with AOC treated within gynaecological cancer centres that participated in the previously presented SOCQER 2 study. National cancer registry datasets were used to identify FIGO Stage 3,4 and unknown stage patients from 11 cancer centres that had previously participated in the SOCQER2 study. Patient outcomes’ association with surgical ethos were evaluated using logistic regression and Cox proportional hazards. Centres were classified into three groups based on their surgical complexity scores (SCS); those practicing mainly low complexity, (5/11 centres with >70% low SCS procedures, 759 patients), mainly intermediate (3/11, 35−50% low SCS, 356 patients), or mainly high complexity surgery (3/11, >35% high SCS, 356 patients). Surgery rates were 43.2% vs. 58.4% vs. 60.9%. across mainly low, intermediate and high SCS centres, respectively, p < 0.001. Combined surgery and chemotherapy rates were 39.2% vs. 51.8% vs. 38.3% p < 0.000 across mainly low, intermediate and high complexity groups, respectively. Median survival was 23.1 (95% CI 19.0 to 27.2) vs. 22.0 (95% CI 17.6 to 26.3) vs. 17.9 months (95% CI 15.7 to 20.1), p = 0.043 in mainly high SCS, intermediate, and low SCS centres, respectively. In an age and deprivation adjusted model, compared to patients in the high SCS centres, patients in the low SCS group had an HR of 1.21 (95% CI 1.03 to 1.40) for death. Mainly high/intermediate SCS centres have significantly higher surgery rates and better survival at a population level. Centres that practice mainly low complexity surgery should change practice. This study provides support for the utilization of URS for patients with advanced OC.

Identifiants

pubmed: 36139523
pii: cancers14184362
doi: 10.3390/cancers14184362
pmc: PMC9497111
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet. 2015 Jul 18;386(9990):249-57
pubmed: 26002111
J Clin Oncol. 2002 Mar 1;20(5):1248-59
pubmed: 11870167
Ann Surg Oncol. 2019 Sep;26(9):2943-2951
pubmed: 31243666
Gynecol Oncol. 2020 Oct;159(1):58-65
pubmed: 32712154
Int J Gynecol Cancer. 2019 Oct;29(8):1327-1331
pubmed: 31420412
Gynecol Oncol. 2017 Jun;145(3):486-492
pubmed: 28372872
J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226
pubmed: 33545690
Gynecol Oncol. 2015 Jan;136(1):11-7
pubmed: 25449311
Gynecol Oncol. 2018 Oct;151(1):24-31
pubmed: 30126704
Cancer. 2009 Mar 15;115(6):1234-44
pubmed: 19189349
Gynecol Oncol. 2013 Nov;131(2):347-51
pubmed: 23954901
BJOG. 2022 Jun;129(7):1122-1132
pubmed: 34865316
Gynecol Oncol. 2017 Jul;146(1):94-100
pubmed: 28411948
Cochrane Database Syst Rev. 2021 Feb 5;2:CD005343
pubmed: 33543776
Int J Epidemiol. 2020 Feb 1;49(1):16-16h
pubmed: 31120104
Gynecol Oncol. 2021 Apr;161(1):244-250
pubmed: 33581846
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:123-139
pubmed: 28457647
Int J Gynecol Cancer. 2020 Apr;30(4):436-440
pubmed: 32086362
Arch Gynecol Obstet. 2017 Mar;295(3):681-687
pubmed: 27995370
Gynecol Oncol. 2004 Sep;94(3):650-4
pubmed: 15350354
N Engl J Med. 2021 Dec 2;385(23):2123-2131
pubmed: 34874631
Am J Obstet Gynecol. 2007 Dec;197(6):676.e1-7
pubmed: 18060979

Auteurs

Carole Cummins (C)

Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TH, UK.

Satyam Kumar (S)

Coventry and Warwickshire Hospitals NHS Trust, Coventry CV2 2DX, UK.

Joanna Long (J)

Institute of Applied Health Research, University of Birmingham, Birmingham B15 2TH, UK.

Janos Balega (J)

Pan Birmingham Gynaecological Cancer Centre, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK.

Tim Broadhead (T)

Leeds Teaching Hospitals NHS Trust, Leeds LS1 9LF, UK.

Timothy Duncan (T)

Norfolk & Norwich University Hospital, Norwich NR4 7UY, UK.

Richard J Edmondson (RJ)

Division of Cancer Sciences, University of Manchester, Manchester M13 9PL, UK.

Christina Fotopoulou (C)

Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London SW7 2BX, UK.

Rosalind M Glasspool (RM)

Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow G12 0YN, UK.

Desiree Kolomainen (D)

Kings College NHS Foundation Trust, London SE5 9RS, UK.

Simon Leeson (S)

Betsi Cadwaladr University Health Board, Bangor LL57 2PW, UK.

Ranjit Manchanda (R)

Wolfson Institute of Population Health, Barts Health NHS Trust, London E1 1BB, UK.

Jo Morrison (J)

Somerset NHS Foundation Trust, Taunton TA1 5DA, UK.

Raj Naik (R)

Northern Gynaecological Oncology Centre, Gateshead NHS Trust, Gateshead NE9 6SX, UK.

John A Tidy (JA)

University of Sheffield, Sheffield S10 2TN, UK.

Nick Wood (N)

Lancashire Teaching Hospitals NHS Foundation Trust, Preston PR7 1PP, UK.

Sudha Sundar (S)

Pan Birmingham Gynaecological Cancer Centre, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK.
Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TH, UK.

Classifications MeSH